- Home
- OM vs CRDF Comparison
OM vs CRDF Comparison
Compare OM & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- CRDF
- Stock Information
- Founded
- OM 2003
- CRDF 1999
- Country
- OM United States
- CRDF United States
- Employees
- OM N/A
- CRDF N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OM Health Care
- CRDF Health Care
- Exchange
- OM Nasdaq
- CRDF Nasdaq
- Market Cap
- OM 220.8M
- CRDF 233.5M
- IPO Year
- OM 2020
- CRDF N/A
- Fundamental
- Price
- OM $14.20
- CRDF $2.32
- Analyst Decision
- OM Hold
- CRDF Strong Buy
- Analyst Count
- OM 1
- CRDF 6
- Target Price
- OM $22.00
- CRDF $10.58
- AVG Volume (30 Days)
- OM 315.6K
- CRDF 2.9M
- Earning Date
- OM 08-06-2025
- CRDF 07-29-2025
- Dividend Yield
- OM N/A
- CRDF N/A
- EPS Growth
- OM N/A
- CRDF N/A
- EPS
- OM N/A
- CRDF N/A
- Revenue
- OM $119,304,000.00
- CRDF $545,000.00
- Revenue This Year
- OM $10.55
- CRDF N/A
- Revenue Next Year
- OM $11.87
- CRDF N/A
- P/E Ratio
- OM N/A
- CRDF N/A
- Revenue Growth
- OM 2.47
- CRDF N/A
- 52 Week Low
- OM $5.85
- CRDF $2.09
- 52 Week High
- OM $25.35
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- OM 44.47
- CRDF 34.12
- Support Level
- OM $13.07
- CRDF $2.22
- Resistance Level
- OM $13.80
- CRDF $2.56
- Average True Range (ATR)
- OM 1.00
- CRDF 0.13
- MACD
- OM 0.20
- CRDF 0.01
- Stochastic Oscillator
- OM 40.48
- CRDF 25.64
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.